Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Pharmacodynamic analysis of AGAVE-201 indicates changes in CSF-1R–expressing cells and associated biomarkers potentially contributing to chronic graft-versus-host disease resolution

View Full Paper
Ask AI
Bookmark
Share

Authors

ICIan M. CatlettBBBreann BarkerSLSong Lou

Discussion

Loading...

Member takes

Overview

Pharmacodynamic analysis shows changes in monocytes and biomarkers in patients with cGVHD, suggesting axatilimab may aid treatment.

Key Points

  • Inflammation and fibrosis are reduced in patients treated with axatilimab for cGVHD, promoting healing.
  • A 74% overall response was achieved with a 0.3 mg/kg dose of axatilimab in AGAVE-201.
  • Proteomic analysis of serum revealed significant changes in biomarkers such as CD163 and keratin 5.
  • These findings highlight the need for further investigation into axatilimab's therapeutic mechanisms in cGVHD.

Cite This Study

Catlett et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e20chttps://doi.org/10.1182/blood-2025-2458
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-2012025 · 1 citations
  2. 2Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program2025 · 1 citations
  3. 3Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Interim safety analysis of a phase 2, randomized study2025 · 1 citations
  4. 4Axatilimab Immunogenicity and Clinical Relevance in Patients with Chronic Graft‐Versus‐Host Disease2025
  5. 5Safety and feasibility of 0.6 mg/kg every 4 weeks dosing of axatilimab in patients treated in the AGAVE-201 study2025 · 1 citations